- Home
- TUYA vs HRMY Comparison
TUYA vs HRMY Comparison
Compare TUYA & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TUYA | HRMY |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TUYA | HRMY |
|---|---|---|
| Price | $2.40 | $32.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $3.49 | ★ $44.11 |
| AVG Volume (30 Days) | 712.3K | ★ 799.5K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.40% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 2.71 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $13.76 | $19.75 |
| Revenue Next Year | $11.90 | $12.88 |
| P/E Ratio | $27.45 | ★ $11.72 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $1.99 | $25.52 |
| 52 Week High | $2.95 | $40.87 |
Technical Indicators
Market Signals| Indicator | TUYA | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 66.25 |
| Support Level | $2.25 | $32.13 |
| Resistance Level | $2.47 | $33.21 |
| Average True Range (ATR) | 0.08 | 1.32 |
| MACD | -0.01 | 0.19 |
| Stochastic Oscillator | 60.02 | 58.88 |
Price Performance
Historical ComparisonAbout TUYA Tuya Inc. each representing one
Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers innovative physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It also provides a complete, open, and neutral global AIoT ecosystem. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.